RJFSA
ESPR

Raymond James Financial Services Advisors’s Esperion Therapeutics ESPR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,635
Closed -$242K – 3330
2021
Q1 		$242K Buy
8,635
+715
+9% +$21.1K ﹤0.01% 2777
2020
Q4 		$206K Hold
7,920
– – ﹤0.01% 2697
2020
Q3 		$294K Sell
7,920
-5,850
-42% -$232K ﹤0.01% 2297
2020
Q2 		$707K Sell
13,770
-2,022
-13% -$84.6K ﹤0.01% 1699
2020
Q1 		$498K Buy
15,792
+3,131
+25% +$165K ﹤0.01% 1559
2019
Q4 		$755K Buy
12,661
+200
+2% +$8.99K ﹤0.01% 1709
2019
Q3 		$457K Sell
12,461
-173
-1% -$6.85K ﹤0.01% 1956
2019
Q2 		$588K Sell
12,634
-196
-2% -$9.21K ﹤0.01% 1818
2019
Q1 		$515K Sell
12,830
-490
-4% -$22K ﹤0.01% 1886
2018
Q4 		$613K Buy
+13,320
New +$642K ﹤0.01% 1535
2018
Q2 		– Sell
-3,870
Closed -$280K – 2804
2018
Q1 		$280K Buy
3,870
+505
+15% +$37.1K ﹤0.01% 2072
2017
Q4 		$222K Buy
+3,365
New +$181K ﹤0.01% 2190

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Raymond James Financial Services Advisors's ESPR Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 8,635 shares — an estimated $242K sold.

Raymond James Financial Services Advisors first reported a position in ESPR in Q4 2017 and held it in 12 quarters. The position peaked at $755K in Q4 2019. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Raymond James Financial Services Advisors reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 8,635 Esperion Therapeutics shares in Q2 2021, an estimated $242K.
  • Raymond James Financial Services Advisors first reported a position in Esperion Therapeutics in Q4 2017 and held it in 12 quarters.
  • Raymond James Financial Services Advisors's Esperion Therapeutics position peaked at $755K in Q4 2019.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.